Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
DOI:
https://doi.org/10.12775/JEHS.2022.12.09.036Keywords
SGLT2, sodium glucose co‐transporter‐2 inhibitors, type 2 diabetes, chronic kidney diseaseAbstract
Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in people with type 2 diabetes. In new researches SGLT2 inhibitors demonstrated a significant and clinically relevant reduction in the risks of albuminuria and progression of nephropathy, doubling of serum creatinine levels, and initiation of renal replacement therapy. This review focuses on the therapeutic effectiveness of using SGLT2 inhibitors for the treatment of CKD in type 2 diabetes.
References
Ene-Iordache B, Perico N, Bikbov B et al (2016) Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health 4:e307–e319
Chantrel F, Ott J, Dimitrov Y et al (2020) Blood pressure control in patients with chronic kidney disease according to office and home blood pressures. Blood Press Monit 25:246–251Return to ref 2 in article
Chen L, Magliano DJ, Zimmet PZ (2011) The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nat Rev Endocrinol 8:228–236
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53.
Ambarsari CG, Tambunan T, Pardede SO et al (2021) Role of dipstick albuminuria in progression of paediatric chronic kidney disease. J Pak Med Assoc S103-S106.
Yamada T, Wakabayashi M, Bhalla A et al (2021) Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 20:14
International Encyclopedia of Public Health (Second Edition)2017, Pages 288-293, Chin Meng Khoo, Diabetes Mellitus Treatment, https://doi.org/10.1016/B978-0-12-803678-5.00108-9.
Nutritional and Therapeutic Interventions for Diabetes and Metabolic Syndrome (Second Edition) 2018, Pages 207-214, Anand S. Nair, Debasis Bagchi, Teresa E. Lehmann, Sreejayan Nair, Chapter 16 - Renal Sodium-Glucose Transporter-2 Inhibitors as Antidiabetic Agents, https://doi.org/10.1016/B978-0-12-812019-4.00016-7.
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24. PMID: 24795251.
Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, Kakiuchi H, Sato Y, Sakai S, Samukawa Y. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin Ther. 2016 Jan 1;38(1):66-88.e20. doi: 10.1016/j.clinthera.2015.10.025. Epub 2015 Dec 22. PMID: 26718606.
Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014 Apr;85(4):962-71. doi: 10.1038/ki.2013.356. Epub 2013 Sep 25. PMID: 24067431; PMCID: PMC3973038.
Lui DTW, Au ICH, Tang EHM, Cheung CL, Lee CH, Woo YC, Wu T, Tan KCB, Wong CKH. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine. 2022 Jun 25;50:101510. doi: 10.1016/j.eclinm.2022.101510. PMID: 35784442; PMCID: PMC9241106.
Lo C, Toyama T, Wang Y, Lin J, Hirakawa Y, Jun M, Cass A, Hawley CM, Pilmore H, Badve SV, Perkovic V, Zoungas S. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD011798. doi: 10.1002/14651858.CD011798.pub2. PMID: 30246878; PMCID: PMC6513625.
De Nicola L, Gabbai FB, Garofalo C, Conte G, Minutolo R. Nephroprotection by SGLT2 inhibition: back to the future? J Clin Med. 2020;9(7):2243. doi: 10.3390/jcm9072243.
Lin J, Wang S, Wen T, Zhang X. Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review. Int Urol Nephrol. 2022 Sep;54(9):2305-2316. doi: 10.1007/s11255-022-03117-4. Epub 2022 Feb 8. PMID: 35133574.
Sato S, Takayanagi K, Shimizu T, Kanozawa K, Iwashita T, Hasegawa H. Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction. Eur J Med Res. 2022 Aug 6;27(1):140. doi: 10.1186/s40001-022-00737-5. PMID: 35933386; PMCID: PMC9356509.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323–34.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–306
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Marcin Czarkowski, Karolina Raksa, Ewelina Powroźniak, Karol Spozowski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 118
Number of citations: 0
